GlassScriptPhysician profile
Shakti Narain
NPI 1689643199
$3,390.65
in general payments reported to CMS, 2019-2025
29 companies · $760 in 2025
The $760 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $397 · 2020: $116 · 2021: $709 · 2022: $622 · 2023: $333 · 2024: $452 · 2025: $760.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,464 · Education: $82.34.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,463.85 |
| Education | $82.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,086.85 | 2019-2025 | Nucala, Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $505.89 | 2019-2025 | Ofev, Spiriva Respimat, Jascayd |
| Astrazeneca Pharmaceuticals LP | $337.32 | 2019-2022 | |
| Insmed, INC. | $235.65 | 2023-2025 | Arikayce, Brinsupri |
| Regeneron Healthcare Solutions, INC. | $142.11 | 2024-2025 | Dupixent |
| Genzyme Corporation | $131.09 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $112.78 | 2021-2022 | |
| Grifols USA, LLC | $89.14 | 2023-2025 | Prolastin-C Liquid |
| Verona Pharma, INC. | $80.47 | 2025 | Ohtuvayre |
| Harmony Biosciences LLC | $79.81 | 2024 | |
| Merck Sharp & Dohme LLC | $77.24 | 2021-2023 | Keytruda |
| Philips North America LLC | $74.25 | 2024-2025 | (Ak6) Vest Therapy, Vest Therapy Und |
| Vapotherm INC | $67.00 | 2022 | |
| Pulmonx Corporation | $62.97 | 2023 | Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter, Zephyr Endobronchial Valve |
| Electromed, INC. | $35.67 | 2023 | Smartvest |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $30.98 | 2019-2022 | |
| Mylan Specialty L.P. | $27.59 | 2020 | |
| Pfizer INC. | $22.88 | 2022 | |
| Advanced Respiratory, INC | $21.61 | 2021 | |
| Hikma Pharmaceuticals USA | $21.41 | 2024 | Ryaltris |
| Novartis Pharmaceuticals Corporation | $19.78 | 2022 | |
| Biogen, INC. | $18.23 | 2020 | |
| Vifor Pharma, INC. | $17.93 | 2024 | Zemaira |
| Gilead Sciences, INC. | $16.84 | 2022 | |
| Lilly USA, LLC | $16.22 | 2025 | Zepbound |
| Actelion Pharmaceuticals US, INC. | $15.10 | 2021 | |
| Circassia INC. | $15.07 | 2019 | |
| Eisai INC. | $15.06 | 2021 | |
| Mallinckrodt Hospital Products INC. | $13.71 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shakti Narain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.